1. Home
  2. NBBK vs FTRE Comparison

NBBK vs FTRE Comparison

Compare NBBK & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBBK

NB Bancorp Inc.

HOLD

Current Price

$19.89

Market Cap

889.5M

Sector

N/A

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$13.31

Market Cap

829.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBBK
FTRE
Founded
1892
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
889.5M
829.3M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
NBBK
FTRE
Price
$19.89
$13.31
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$23.50
$14.06
AVG Volume (30 Days)
342.8K
1.5M
Earning Date
04-22-2026
05-05-2026
Dividend Yield
1.43%
N/A
EPS Growth
25.23
N/A
EPS
0.36
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
$45.15
N/A
Revenue Next Year
$4.18
$3.09
P/E Ratio
$55.22
N/A
Revenue Growth
N/A
1.00
52 Week Low
$15.44
$3.97
52 Week High
$22.86
$18.67

Technical Indicators

Market Signals
Indicator
NBBK
FTRE
Relative Strength Index (RSI) 45.25 55.18
Support Level $19.32 $8.85
Resistance Level $20.67 $18.26
Average True Range (ATR) 0.37 0.78
MACD 0.05 -0.23
Stochastic Oscillator 48.59 9.69

Price Performance

Historical Comparison
NBBK
FTRE

About NBBK NB Bancorp Inc.

NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: